The treatment landscape for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer has expanded significantly, with 3 FDA-approved bladder-sparing therapies now available: pembrolizumab, ...

Key Takeaways Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab ...

Physician Summary: Overcoming Challenges in Accessing New Therapies for NMIBC Access to new therapies for non-muscle invasive bladder cancer (NMIBC) presents several challenges, including cost, ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

The concept of BCG-unresponsive non–muscle-invasive bladder cancer has evolved significantly since its introduction in 2015. This designation is crucial for identifying patients who have received an ...

Key Takeaways Non-Hispanic Black and Latinx patients with prostate cancer are less likely to receive PSMA-PET imaging than non-Hispanic White patients, indicating racial/ethnic disparities. The study ...

Panelists discuss emerging data comparing bladder-sparing therapies to radical cystectomy in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting the nuanced trade-offs in ...

The cornerstone for first-line treatment in metastatic prostate cancer is androgen deprivation therapy (ADT), although there are several other options that can be used to personalize treatment to the ...

Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

In a recent interview, Rebecca A. Campbell, MD, a urologic oncology fellow at Cleveland Clinic in Cleveland, Ohio, discussed concrete steps to mitigate gender-based disparities in Altmetric Attention ...

In the phase 2 COMRADE trial (NCT03317392), reduced-dose olaparib (Lynparza) combined with radium-223 (Ra-223, Xofigo) significantly improved radiographic progression-free survival (rPFS) over Ra-223 ...